FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.

FDA Warns Consumers Not to Use the Dietary Supplement Lipokinetix

The Food and Drug Administration (FDA) is warning consumers immediately to stop use of the product Lipokinetix®, marketed as a dietary supplement by Syntrax Innovations, Inc. Lipokinetix has been implicated in a number of serious liver injuries. FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix.

Lipokinetix is marketed for weight loss. It contains the ingredients norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of Lipokinetix. Liver injury developed between 2 weeks and 3 months of Lipokinetix use.

FDA urges consumers to discontinue use of Lipokinetix and consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. Consumers or health care professionals who are aware of adverse effects after the use of this or other dietary supplement products can report the adverse event to FDA's MedWatch adverse event and product problem hot line at 1-800-FDA-1088 or via the internet (http://www.fda.gov/medwatch/how.htm).

####

For further information, see www.fda.gov/medwatch/safety/2001/safety01.htm#lipoki

FDA News Page   |   FDA Home Page

Office of Public Affairs
Web page uploaded by tg 2001-NOV-20.